Peptides Similar to Rusfertide
Compare Rusfertide with related peptides and alternatives
📌TL;DR
- •1 similar peptides identified
- •EPO (Erythropoietin): Moderate - Both act on erythropoiesis but with opposite effects. EPO stimulates red blood cell production; rusfertide restricts it by limiting iron supply. Both are peptide-based therapies targeting hematological conditions.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Rusfertide (current) | - | - |
| EPO (Erythropoietin) | Moderate - Both act on erythropoiesis but with opposite effects. EPO stimulates red blood cell production; rusfertide restricts it by limiting iron supply. Both are peptide-based therapies targeting hematological conditions. | Opposite mechanisms: EPO promotes erythropoiesis for anemia while rusfertide restricts erythropoiesis for polycythemia. EPO is an approved recombinant protein; rusfertide is an investigational synthetic peptide. |
Similarities and differences between Rusfertide and related peptides
Infographic pending generation
Peptides Related to Rusfertide#
Rusfertide occupies a unique position as the first hepcidin mimetic in late-stage clinical development. There are no other approved or late-stage hepcidin mimetics for direct comparison. The most relevant comparisons are with other approaches to managing erythrocytosis in polycythemia vera and with peptide-based therapies targeting the erythropoiesis pathway.
Ruxolitinib (Jakafi)#
Ruxolitinib is an oral JAK1/JAK2 inhibitor approved for PV in patients with inadequate response to or intolerance of hydroxyurea. As the only approved targeted therapy for PV, it is the most relevant clinical comparator.
Mechanism comparison: Ruxolitinib directly inhibits the JAK2 signaling pathway that drives the myeloproliferative phenotype. This addresses the underlying driver of PV at the signaling level. Rusfertide acts downstream by restricting iron supply for erythropoiesis, without directly targeting the JAK2 clone.
Clinical positioning: Ruxolitinib is typically used as second-line cytoreductive therapy. Rusfertide is positioned to address the specific problem of erythrocytosis and phlebotomy burden, potentially as an add-on to existing therapy rather than a replacement.
| Parameter | Rusfertide | Ruxolitinib |
|---|---|---|
| Class | Hepcidin mimetic peptide | JAK1/JAK2 inhibitor |
| Route | Subcutaneous weekly | Oral twice daily |
| Target | Ferroportin/iron metabolism | JAK2 signaling |
| Primary effect | Erythrocytosis control | Splenomegaly + symptom control |
| Phlebotomy reduction | Primary endpoint | Secondary benefit |
| Cytoreductive | No | Yes |
| Regulatory status | Phase 3 (BTD) | FDA-approved (2014) |
Hydroxyurea#
Hydroxyurea is the most widely used first-line cytoreductive agent for PV. It is an oral antimetabolite that suppresses bone marrow proliferation non-specifically.
Key differences: Hydroxyurea acts broadly on all proliferating cells, causing myelosuppression, while rusfertide specifically targets iron metabolism for erythropoiesis control. Hydroxyurea has known risks including leukemogenic potential with long-term use, while rusfertide's safety profile is limited to injection site reactions and iron restriction.
Complementary roles: In clinical trials, rusfertide has been used concomitantly with hydroxyurea, suggesting a complementary rather than competitive relationship.
Interferon Alfa (Ropeginterferon)#
Ropeginterferon alfa-2b (Besremi) is approved for PV as a non-chemotherapeutic cytoreductive option. It targets the PV clone through immune modulation and can reduce JAK2 allele burden over time.
Key differences: Interferon addresses the underlying clonal disease and may achieve molecular responses. Rusfertide targets erythrocytosis specifically through iron restriction. Interferon has a broader adverse effect profile including autoimmune phenomena, depression, and flu-like symptoms.
EPO (Erythropoietin)#
EPO is included as a comparison because both are peptide-based agents acting on erythropoiesis, albeit in opposite directions. EPO stimulates erythropoiesis for anemia treatment, while rusfertide restricts it for PV management.
Summary Comparison#
| Feature | Rusfertide | Ruxolitinib | Hydroxyurea | Ropeginterferon |
|---|---|---|---|---|
| Mechanism | Iron restriction | JAK inhibition | Antimetabolite | Immune modulation |
| Primary target | Erythrocytosis | Symptoms/splenomegaly | Cytoreduction | Clonal suppression |
| Route | SC weekly | Oral BID | Oral daily | SC Q2W |
| Cytoreductive | No | Yes | Yes | Yes |
| Molecular response | No | Minimal | No | Yes (JAK2 allele) |
| Key AEs | ISRs, iron restriction | Cytopenias, infections | Myelosuppression | Autoimmune, flu-like |
| Regulatory | Phase 3 | Approved | Approved | Approved |
Related Reading#
Frequently Asked Questions About Rusfertide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer